Prometic's pivotal IVIG phase 3 trial to treat primary immunodeficiencies meets primary and secondary endpoints

Prometic Life Sciences Inc. (Prometic) announced positive clinical data from its pivotal IVIG phase 3 clinical trial, meeting its clinical primary and secondary endpoints in adult patients suffering from primary immunodeficiencies (PID).

More From BioPortfolio on "Prometic's pivotal IVIG phase 3 trial to treat primary immunodeficiencies meets primary and secondary endpoints"